Ocumension Therapeutics has announced that its product, OT-703 (ILUVIEN®), has been approved for a real-world study in the Boao Lecheng International Medical Tourism Pilot Zone in Hainan Province, China. OT-703 is an injectable, non-biodegradable fluocinolone acetate intravitreal implant designed for the treatment of diabetic macular edema $(DME.AU)$. The implant provides a continuous microdose of corticosteroid fluocinolone acetonide in the eye for up to 36 months. It is the only FDA-approved corticosteroid intraocular implant with a three-year sustained-release period, and it has recently received regulatory approval in Hong Kong. Ocumension holds exclusive rights for its development and commercialization in Greater China, South Korea, and parts of Southeast Asia, following a licensing agreement with Alimera Sciences, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。